Welcome to CSNpharm! For Research Use Only!
IRAK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN16588 | SC144 | 895158-95-9 | SC144 showed its function through both exhibiting potent cytotoxicity, by itself or synergism with other compounds, against a panel of drug-sensitive and drug-resistant cancer cell lines, and targeting to gp130. |
| CSN18657 | Zimlovisertib | 1817626-54-2 | PF-06650833 is an inhibitor ofInterleukin-1 receptor associated kinase 4 (IRAK4), and used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas. |
| CSN50540 | JH-X-119-01 | 2227368-54-7 | Jh-X-119-01 is a novel potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. |
| CSN25328 | IRAK4-IN-4 | 1850276-58-2 | IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor with IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with IC50 of 2.1 nM. |
| CSN18307 | IRAK-1-4 Inhibitor I | 509093-47-4 | IRAK-1-4 Inhibitor I is a IRAK-4 inhibitor with IC50 of 200 nM. |
| CSN17419 | IRAK inhibitor 6 | 1042672-97-8 | IRAK Inhibitor 6 is an improved IRAK-4 inhibitor with IC50 value of 160 nM. |
| CSN19007 | IRAK inhibitor 4 trans | 2070014-89-8 | IRAK inhibitor 4 trans is the trans form of IRAK inhibitor 4,which is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. |
| CSN17391 | IRAK inhibitor 4 | 1012104-68-5 | IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. |
| CSN17392 | IRAK inhibitor 3 | 1012343-93-9 | IRAK inhibitor 3 is an interleukin-1 receptor associated kinase inhibitor. |
| CSN18593 | IRAK inhibitor 2 | 928333-30-6 | IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor . |
| CSN17418 | IRAK inhibitor 1 | 1042224-63-4 | IRAK inhibitor 1 is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor. |
| CSN21077 | IRAK4-IN-7 | 1801343-74-7 | CA-4948 is a selective and potent IRAK4 inhibitor which can be used as a therapeutic agent for hematological cancers with dysregulated TLRMYD88IRAK4 signaling CA-4948 exhibits favorable DMPK properties oral bioavailability and is well tolerated in mice Furthermore CA-4948 is previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models |
| CSN28782 | Emavusertib | 1801344-14-8 | CA-4948 is a selective and orally bioavailable IRAK4 Inhibitor. It exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. |
| CSN32995 | BMS-986147 | 1800553-97-2 | BMS-986147 is an IRAK-4 inhibitor, that was in early clinical development at Bristol-Myers Squibb in healthy volunteers; however, no recent development has been reported. |
| CSN22689 | AS2444697 | 1287665-60-4 | AS 2444697 is a potent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with IC50 of 21 nM. |
| CSN24907 | Anthraquinone-2-carboxylic acid | 117-78-2 | Anthraquinone-2-carboxylic acid acts as a potent anti-inflammatory and antinociceptive component in vivo, thus contributing to the immune regulatory role of fruits and herbs. |
| CSN32739 | PF-06426779 | 1817628-40-2 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
